The chief executive of Tissue Regenix Group PLC (LON:TRX) is to return to full-time duties next month.
At the end of last year, the regenerative medicines specialist confirmed Steve Couldwell would be taking a temporary leave of absence to undergo medical treatment.
READ: Tissue Regenix secures additional coverage for DermaPure from US GPO
“The board and I look forward to welcoming Steve back into the full time CEO position and are grateful for his ongoing commitment,” said chairman John Samuel, who held the fort whilst Couldwell was away.
“During his necessary absence Steve remained in daily contact with the business and continued to be integral to implementing the business strategy and establishing future business developments, along with the support of Gareth Jones who undertook the chief operating officer role during this period.”
Samuel added: “The business has continued to develop in line with the board expectations.”